List of Treximet drug patents

Treximet is owned by Currax.

Treximet contains Naproxen Sodium; Sumatriptan Succinate.

Treximet has a total of 2 drug patents out of which 0 drug patents have expired.

Treximet was authorised for market use on 15 April, 2008.

Treximet is available in tablet;oral dosage forms.

Treximet can be used as treatment of migraine; acute treatment of migraine.

The generics of Treximet are possible to be released after 02 April, 2026.

TREXIMET Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7332183 CURRAX Multilayer dosage forms containing NSAIDs and triptans
Oct, 2025

(2 years from now)

US7332183

(Pediatric)

CURRAX Multilayer dosage forms containing NSAIDs and triptans
Apr, 2026

(2 years from now)

Do you want to check out TREXIMET patents from before 2022?

Drugs and Companies using NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 15 April, 2008

Treatment: Treatment of migraine; Acute treatment of migraine

Dosage: TABLET;ORAL

How can I launch a generic of TREXIMET before it's patent expiration?
More Information on Dosage

TREXIMET family patents

3

United States

2

Norway

1

Spain

1

Austria

1

Cyprus

1

Israel

1

Canada

1

Portugal

1

Lithuania

1

Denmark

1

Mexico

1

Japan

1

Australia

1

Slovenia

1

Hungary

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in